P Tarantino, G Viale, M F Press, X Hu, F Penault-Llorca, A Bardia, A Batistatou, H J Burstein, L A Carey, J Cortes, C Denkert, V Diéras, W Jacot, A K Koutras, A Lebeau, S Loibl, S Modi, M F Mosele, E Provenzano, G Pruneri, J S Reis-Filho, F Rojo, R Salgado, P Schmid, S J Schnitt, S M Tolaney, D Trapani, A Vincent-Salomon, A C Wolff, G Pentheroudakis, F André, G Curigliano
Human epidermal growth factor receptor 2 (HER2)-low breast cancer has recently emerged as a targetable subset of breast tumors, based on the evidence from clinical trials of novel anti-HER2 antibody-drug conjugates. This evolution has raised several biological and clinical questions, warranting the establishment of consensus to optimally treat patients with HER2-low breast tumors. Between 2022 and 2023, the European Society for Medical Oncology (ESMO) held a virtual consensus-building process focused on HER2-low breast cancer...
August 2023: Annals of Oncology: Official Journal of the European Society for Medical Oncology